Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Rating of “Buy” by Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have earned an average rating of “Buy” from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $16.00.

A number of equities research analysts have commented on the company. HC Wainwright raised their target price on Inventiva from $20.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, October 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research note on Wednesday, October 8th. Canaccord Genuity Group restated a “buy” rating and set a $20.00 target price on shares of Inventiva in a research report on Tuesday, September 30th. UBS Group started coverage on shares of Inventiva in a report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 target price for the company. Finally, Wolfe Research raised Inventiva to a “strong-buy” rating in a research note on Thursday, November 6th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IVA. Creative Planning purchased a new stake in shares of Inventiva in the 2nd quarter worth about $32,000. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Inventiva by 54.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock valued at $50,000 after purchasing an additional 5,843 shares in the last quarter. NewEdge Advisors LLC acquired a new stake in shares of Inventiva in the third quarter valued at approximately $116,000. Finally, Millennium Management LLC purchased a new position in shares of Inventiva during the 3rd quarter worth approximately $649,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Price Performance

IVA opened at $7.15 on Friday. Inventiva has a 12 month low of $2.15 and a 12 month high of $7.98. The business has a 50 day simple moving average of $4.80 and a 200-day simple moving average of $4.69.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.